Novel Targets is a podcast about the science and people involved in the development of innovative new drugs, gene and cell therapies. To date we’ve focused on cancer drug development and in particular some of the latest cancer immunotherapy research.
The show looks at some of the emerging new targets and approaches that could make a difference to the lives of patients. It discusses data from clinical trials and engages experts.
The aim is to inform, educate and create awareness. It occasionally entertains.
Follow the Podcast on Twitter: @TargetsPodcast
Sally Church, PhD
Sally is the executive producer of Novel Targets and ensures the scientific accuracy of the show’s output.
A member of the National Association of Science Writers (NASW) and Association of Health Care Journalists (AHCJ), Sally has over the last 10 years written over a thousand blog posts on cancer drug development on Pharma Strategy Blog; she now writes on Biotech Strategy Blog.
Follow Sally on Twitter: @MaverickNY
Pieter is the host and producer of Novel Targets.
Follow Pieter on Twitter: @3NT
Genentech (@Genentech) have sponsored Seasons 1 to 3 of the podcast. They recently advised they will renew their support for 5 episodes in Season 4. We’re grateful for their support!
Each episode Genentech supports usually features a short vignette or mini-interview with one of their scientists that highlights their passion in “helping people combat the world’s hardest-to-treat diseases.”
The Loncar Cancer Immunotherapy Index sponsored Episode 14: Cell Therapy Pioneers. It reached No 21 in the US iTunes chart for Medicine podcasts.
Novel Targets reaches a broad global audience of “influencers” interested in the latest cancer research.
It’s frequently ranked in the top 200 Medicine podcasts on iTunes. It’s also distributed via Soundcloud and Google Play.
Please contact us if you would like to discuss sponsorship of an episode or mini-series themed around a conference, target or disease area.
If we do mention any products or people from any sponsor (outside of the sponsorship mention), then it’s because they merit commentary or inclusion – there is no “quid pro quo.”
The podcast is editorially independent – we say what we want to say – sponsors have no control over content, who we interview, what topics we talk about or the questions we ask!
The podcast is not about promoting anybody’s product nor is it a vehicle for corporate messages. We think an editorially independent podcast makes the content more likely to be shared and listened to.